CY1123345T1 - Αναλογα υποκατεστημενου (ε)-ν'-(1-φαινυλαιθυλιδενο) βενζοϋδραζιδιου ως αναστολεiς απομεθυλασης ιστονης - Google Patents
Αναλογα υποκατεστημενου (ε)-ν'-(1-φαινυλαιθυλιδενο) βενζοϋδραζιδιου ως αναστολεiς απομεθυλασης ιστονηςInfo
- Publication number
- CY1123345T1 CY1123345T1 CY20201100866T CY201100866T CY1123345T1 CY 1123345 T1 CY1123345 T1 CY 1123345T1 CY 20201100866 T CY20201100866 T CY 20201100866T CY 201100866 T CY201100866 T CY 201100866T CY 1123345 T1 CY1123345 T1 CY 1123345T1
- Authority
- CY
- Cyprus
- Prior art keywords
- substituted
- compounds
- benzohydrazide
- inhibitors
- phenylethylydene
- Prior art date
Links
- 108010033040 Histones Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical class NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 title 1
- 230000017858 demethylation Effects 0.000 title 1
- 238000010520 demethylation reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 abstract 2
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 abstract 2
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 abstract 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- HAUVWRQIVOPGOE-FOWTUZBSSA-N n-[(e)-1-phenylethylideneamino]benzamide Chemical class C=1C=CC=CC=1C(/C)=N/NC(=O)C1=CC=CC=C1 HAUVWRQIVOPGOE-FOWTUZBSSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523801P | 2011-08-15 | 2011-08-15 | |
| PCT/US2012/050948 WO2013025805A1 (en) | 2011-08-15 | 2012-08-15 | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123345T1 true CY1123345T1 (el) | 2022-03-24 |
Family
ID=47715455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100866T CY1123345T1 (el) | 2011-08-15 | 2020-09-14 | Αναλογα υποκατεστημενου (ε)-ν'-(1-φαινυλαιθυλιδενο) βενζοϋδραζιδιου ως αναστολεiς απομεθυλασης ιστονης |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8987335B2 (https=) |
| EP (1) | EP2744330B1 (https=) |
| JP (1) | JP6122006B2 (https=) |
| KR (1) | KR101983537B1 (https=) |
| CN (1) | CN103929960B (https=) |
| AU (1) | AU2012296639B2 (https=) |
| BR (1) | BR112014003382B1 (https=) |
| CA (1) | CA2843609C (https=) |
| CY (1) | CY1123345T1 (https=) |
| DK (1) | DK2744330T3 (https=) |
| EA (1) | EA026389B1 (https=) |
| ES (1) | ES2821548T3 (https=) |
| HK (1) | HK1200052A1 (https=) |
| HR (1) | HRP20201433T1 (https=) |
| HU (1) | HUE050962T2 (https=) |
| IL (1) | IL230728A (https=) |
| IN (1) | IN2014CN00961A (https=) |
| LT (1) | LT2744330T (https=) |
| MX (1) | MX356486B (https=) |
| PL (1) | PL2744330T3 (https=) |
| PT (1) | PT2744330T (https=) |
| SG (1) | SG2014009609A (https=) |
| SI (1) | SI2744330T1 (https=) |
| SM (1) | SMT202000551T1 (https=) |
| WO (1) | WO2013025805A1 (https=) |
| ZA (1) | ZA201400881B (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9266838B2 (en) | 2011-08-15 | 2016-02-23 | University Of Utah Research Foundation | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
| DK2903968T3 (en) | 2012-10-02 | 2017-01-30 | Gilead Sciences Inc | INHIBITORS OF HISTON DEMETHYLASES |
| PE20151667A1 (es) | 2013-02-27 | 2015-11-27 | Epitherapeutics Aps | Inhibidores de histona desmetilasas |
| US9738637B2 (en) * | 2013-03-12 | 2017-08-22 | Celgene Quantical Research, Inc. | Histone demethylase inhibitors |
| BR112015032113B1 (pt) * | 2013-06-19 | 2019-01-29 | University Of Utah Research Foundation | análogos de (e)-n’-(1-feniletilideno)benzohidrazida substituídos como inibidores de histona demetilase |
| JP6602779B2 (ja) | 2014-02-13 | 2019-11-06 | インサイト・コーポレイション | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| EP3105218B1 (en) | 2014-02-13 | 2019-09-25 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US10807944B2 (en) | 2014-04-04 | 2020-10-20 | University Of Florida Research Foundation, Inc. | HDAC inhibitor compounds and methods of treatment |
| EP3151821A4 (en) * | 2014-06-05 | 2017-12-13 | The University of Kansas | Marmelin analogs and methods of use in cancer treatment |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| SG11201701182VA (en) | 2014-08-27 | 2017-03-30 | Gilead Sciences Inc | Compounds and methods for inhibiting histone demethylases |
| EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
| CN106146361A (zh) * | 2015-03-16 | 2016-11-23 | 四川大学 | 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途 |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| AU2016275702A1 (en) | 2015-06-12 | 2017-12-21 | Oryzon Genomics, S.A. | Biomarkers associated with LSD1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| WO2017158136A1 (en) | 2016-03-16 | 2017-09-21 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| TWI833686B (zh) * | 2016-04-22 | 2024-03-01 | 美商英塞特公司 | Lsd1 抑制劑之調配物 |
| EP3246330A1 (en) | 2016-05-18 | 2017-11-22 | Istituto Europeo di Oncologia S.r.l. | Imidazoles as histone demethylase inhibitors |
| WO2018017589A1 (en) | 2016-07-19 | 2018-01-25 | The General Hospital Corporation | Compounds for targeting cancer stem cells |
| EP3535414A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| MA51507A (fr) | 2016-12-09 | 2020-11-11 | Constellation Pharmaceuticals Inc | Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1 |
| CN106831489B (zh) * | 2017-03-23 | 2018-04-17 | 郑州大学 | 苯环丙胺酰腙类化合物、制备方法及其应用 |
| FI3661510T3 (fi) | 2017-08-03 | 2024-12-18 | Oryzon Genomics Sa | Menetelmiä käyttäytymismuutosten hoitamiseksi |
| ES2986559T3 (es) | 2017-08-18 | 2024-11-11 | St Europeo Di Oncologia S R L | Derivados de indol como inhibidores de la histona desmetilasa |
| WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| CN109793742A (zh) * | 2019-03-04 | 2019-05-24 | 四川大学华西医院 | 一种药物化合物应用 |
| CN109758442B (zh) * | 2019-03-20 | 2021-08-17 | 武汉大学 | 二芳基酰肼类化合物在制备抗流感病毒药物中的应用 |
| US20220151999A1 (en) | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| LT3941466T (lt) | 2019-03-20 | 2026-02-25 | Oryzon Genomics, S.A. | Vafidemstatas ribinio asmenybės sutrikimo simptomų, nesusijusių su agresija, gydymui |
| CN114341366A (zh) | 2019-07-05 | 2022-04-12 | 奥莱松基因组股份有限公司 | 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法 |
| US20220047528A1 (en) * | 2020-07-24 | 2022-02-17 | Salarius Pharmaceuticals Llc | Methods of inhibiting lysine-specific demethylase 1 (lsd-1) |
| EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
| US20250073232A1 (en) | 2021-04-08 | 2025-03-06 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| CN116077661B (zh) * | 2022-08-22 | 2024-09-27 | 沈阳药科大学 | Kdm1a抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途 |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004525118A (ja) * | 2001-01-22 | 2004-08-19 | アルパイダ アーゲー | 新規ヒドラゾン類 |
| JP2002302472A (ja) * | 2001-01-31 | 2002-10-18 | Meiji Seika Kaisha Ltd | メイラード反応阻害剤 |
| JPWO2005007151A1 (ja) | 2003-07-16 | 2006-08-31 | 株式会社医薬分子設計研究所 | 皮膚色素沈着の治療剤 |
| WO2006136008A1 (en) | 2005-05-24 | 2006-12-28 | University Health Network | Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer |
| TW200800145A (en) * | 2005-08-26 | 2008-01-01 | Dekk Tec Inc | Hydrazone agents to treat cutaneous lesions |
| EP1951215A4 (en) | 2005-11-03 | 2009-07-29 | Redpoint Bio Corp | HYDRAZONE DERIVATIVES AND ITS USES |
| WO2008066887A2 (en) | 2006-11-30 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of bcl6 |
| AU2008214338A1 (en) | 2007-02-02 | 2008-08-14 | Redpoint Bio Corporation | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release |
| EP2142498A2 (en) * | 2007-04-02 | 2010-01-13 | Institute for Oneworld Health | Cftr inhibitor compounds and uses thereof |
| WO2009027349A2 (en) * | 2007-08-24 | 2009-03-05 | Oryzon Genomics Sa | Treatment and prevention of neurodegenerative diseases |
| AR070898A1 (es) * | 2008-03-18 | 2010-05-12 | Solvay Pharm Bv | Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6 |
| JP2011526925A (ja) | 2008-07-01 | 2011-10-20 | ザカロン ファーマシューティカルズ，インク． | ヘパラン硫酸阻害剤 |
| WO2010083314A2 (en) * | 2009-01-14 | 2010-07-22 | Dow Agrosciences Llc | Fungicidal compositions including hydrazone derivatives and copper |
| US20110189306A1 (en) * | 2010-01-13 | 2011-08-04 | Norbert Kartner | COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES |
-
2012
- 2012-08-15 SI SI201231841T patent/SI2744330T1/sl unknown
- 2012-08-15 ES ES12823540T patent/ES2821548T3/es active Active
- 2012-08-15 IN IN961CHN2014 patent/IN2014CN00961A/en unknown
- 2012-08-15 WO PCT/US2012/050948 patent/WO2013025805A1/en not_active Ceased
- 2012-08-15 EP EP12823540.5A patent/EP2744330B1/en active Active
- 2012-08-15 AU AU2012296639A patent/AU2012296639B2/en active Active
- 2012-08-15 HU HUE12823540A patent/HUE050962T2/hu unknown
- 2012-08-15 JP JP2014526170A patent/JP6122006B2/ja active Active
- 2012-08-15 MX MX2014001842A patent/MX356486B/es active IP Right Grant
- 2012-08-15 HK HK15100490.8A patent/HK1200052A1/xx unknown
- 2012-08-15 DK DK12823540.5T patent/DK2744330T3/da active
- 2012-08-15 LT LTEP12823540.5T patent/LT2744330T/lt unknown
- 2012-08-15 CA CA2843609A patent/CA2843609C/en active Active
- 2012-08-15 KR KR1020147006969A patent/KR101983537B1/ko active Active
- 2012-08-15 HR HRP20201433TT patent/HRP20201433T1/hr unknown
- 2012-08-15 SG SG2014009609A patent/SG2014009609A/en unknown
- 2012-08-15 PT PT128235405T patent/PT2744330T/pt unknown
- 2012-08-15 CN CN201280050736.9A patent/CN103929960B/zh active Active
- 2012-08-15 PL PL12823540T patent/PL2744330T3/pl unknown
- 2012-08-15 US US13/586,603 patent/US8987335B2/en active Active
- 2012-08-15 SM SM20200551T patent/SMT202000551T1/it unknown
- 2012-08-15 EA EA201490453A patent/EA026389B1/ru unknown
- 2012-08-15 BR BR112014003382-0A patent/BR112014003382B1/pt active IP Right Grant
-
2014
- 2014-01-30 IL IL230728A patent/IL230728A/en active IP Right Grant
- 2014-02-05 ZA ZA2014/00881A patent/ZA201400881B/en unknown
-
2015
- 2015-02-16 US US14/623,370 patent/US9555024B2/en not_active Expired - Fee Related
-
2020
- 2020-09-14 CY CY20201100866T patent/CY1123345T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123345T1 (el) | Αναλογα υποκατεστημενου (ε)-ν'-(1-φαινυλαιθυλιδενο) βενζοϋδραζιδιου ως αναστολεiς απομεθυλασης ιστονης | |
| CY1122556T1 (el) | Υποκατεστημενα αναλογα ν-φαινυλπυριμιδιν-2- αμινης ως αναστολεις της κινασης axl | |
| CY1122988T1 (el) | Υπογλωσσια υμενια | |
| CY1121625T1 (el) | Αναστολεις prmt5 και χρησεις αυτων | |
| IL243200B (en) | Converted analogs of (e)-n'-(1-phenylethylidene)benzohydrazide as histone demethylase inhibitors | |
| HRP20180239T1 (hr) | Deuterirani derivati benzokinolizina kao inhibitori vezikularnog monoaminskog transportera 2 | |
| CY1117760T1 (el) | Συνδυασμος ενωσεων μορφινανης και αντικαταθλιπτικου για την αγωγη του ψευδοπρομηκικου συναισθηματος | |
| WO2014194280A3 (en) | Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells | |
| CY1117471T1 (el) | Αμιδια πυρρολοπυραζινης-σπειροκυκλικης πιπεριδινης ως ρυθμιστες διαυλων ιοντος | |
| CY1120438T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει μυο-ινοσιτολη και d-κιρο-ινοσιτολη | |
| CY1118352T1 (el) | Νεα παραγωγα κυκλοεξυλαμινης με δρασεις β2 αδρενεργικου αγωνιστη και μ3 μουσκαρινικου ανταγωνιστη | |
| CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
| BR112016008541A2 (pt) | composições úteis para tratar distúrbios relacionados a kit | |
| BRPI1012638B8 (pt) | métodos e intermediários para preparar agentes farmacêuticos | |
| GT201300254A (es) | Triazolopiridinas | |
| BR112013020767A2 (pt) | composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo | |
| BR112014010713A2 (pt) | compostos com atividade nematicida | |
| CL2013002664A1 (es) | Compuestos derivados heterociclicos de amina; afines a receptores asociados a mina traza taar1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la depresion, ansiedad, parkinson, trastorno bipolar, de hiperactividad con deficit atencional, relacionados con estres, y otros. | |
| BR112016008644A2 (pt) | Inibidor de dinamina 2 para uso no tratamento de uma miopatia centronuclear; método para identificar ou triar moléculas úteis no tratamento de uma miopatia centronuclear, de preferência, xlcnm; e composição farmacêutica | |
| CY1121081T1 (el) | Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων | |
| CY1115577T1 (el) | Μεθοδος για την παρασκευη εναντιομερικως καθαρων αμινων | |
| CU24550B1 (es) | Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos | |
| CY1119748T1 (el) | Υποκατασταθεντα 2-αλκυλ-1-οξο-ν-φαινυλ-3-ετεροαρυλ-1,2,3,4-τετραϋδροϊσοκινολιν-4-καρβοξαμιδια για ανθελονοσιακες θεραπειες | |
| AR080025A1 (es) | Derivados de 8-aza-biciclo[3,2,1] oct-3-iloxi)-cromen-2-ona, utiles como inhibidores de la recaptacion del neurotransmisor monoamina | |
| BR112014009760A2 (pt) | análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo |